DT-Web

DB01624 - Zuclopenthixol


Identification
Name Zuclopenthixol
Accession Number DB01624
Type small molecule
Description A thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. [PubChem]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 400.965
Groups approved
Monoisotopic Weight 400.137611829
Pharmacology
Indication For the management of the manifestations of schizophrenia.
Mechanism of action Zuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene group. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
Absorption Not Available
Protein binding Approximately 98%.
Biotransformation The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity.
Route of elimination Not Available
Toxicity Although there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Abarelix Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Amantadine Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Amiodarone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Amitriptyline Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Amoxapine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Apomorphine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Antagonism may also occur between zuclopenthixol, a dopamine D2 receptor antagonist, and apomorphine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Arsenic trioxide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Asenapine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Azithromycin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Bromocriptine Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Bupropion Bupropion, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if bupropion is initiated, discontinued or dose changed.
Chlorpromazine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed.
Cinacalcet Cinacalcet, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cinacalcet is initiated, discontinued or dose changed.
Cisapride Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Citalopram Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Clarithromycin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Clomipramine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Cocaine Cocaine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cocaine is initiated, discontinued or dose changed.
Dasatinib Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Delavirdine Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed.
Desipramine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Disopyramide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Dofetilide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Dolasetron Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Domperidone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Donepezil Possible antagonism of action
Doxepin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Dronedarone Additive or synergistic QTc-prolonging effects may occur. Concomitant therapy is contraindicated.
Droperidol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Erythromycin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Escitalopram Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Etravirine Zuclopenthixol (especially oral dosage form) may experience a decrease in serum concentration when used concomitantly with etravirine. It is recommended to monitor zuclopenthixol therapy for efficacy.
Flecainide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Fluconazole Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Fluoxetine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed.
Flupenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Foscarnet Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Galantamine Possible antagonism of action
Halofantrine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Haloperidol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ibutilide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Iloperidone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Imipramine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Indapamide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Isradipine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Lapatinib Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Levodopa Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Levofloxacin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Lopinavir Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed.
Loxapine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Maprotiline Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Mefloquine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Mesoridazine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Methadone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Methotrimeprazine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed.
Metoclopramide Additive dopamine D2 receptor antagonism may cause dopaminergic imbalance in the nigrostriatal (dopamine D1 receptors) and striatopallidal (dopamine D2 receptors). Increased risk of extrapyramidal reactions and neuroleptic malignant syndrome. Concomitant therapy should be avoided.
Moxifloxacin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Nilotinib Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.
Norfloxacin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Nortriptyline Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Octreotide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Paroxetine Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed.
Pazopanib Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Pentamidine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Perflutren Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Pergolide Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed.
Pimozide Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
Pramipexole Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pramipexole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Pramlintide May cause additive reduction in GI motility. Use caution or consider alternate therapy.
Probucol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Procainamide Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Propafenone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Protriptyline Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Quetiapine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Quinidine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Quinidine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if quinidine is initiated, discontinued or dose changed.
Quinine Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.
Ranolazine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Risperidone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ritonavir Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed.
Romidepsin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ropinirole Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Rotigotine Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and rotigotine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.
Sotalol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Sparfloxacin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Sunitinib Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Tacrine The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Zuclopenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
Tacrolimus Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Telavancin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Telithromycin Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Terbinafine Terbinafine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if terbinafine is initiated, discontinued or dose changed.
Tetrabenazine Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided.
Thioridazine Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
Thiothixene Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
Trimethobenzamide Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Trimipramine Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Triprolidine Triprolidine and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Trospium Trospium and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Voriconazole Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
Food Interactions Not Available

Targets


D(1A) dopamine receptor
Name D(1A) dopamine receptor
Gene Name DRD1
Pharmacological action yes
Actions antagonist
References
  • Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. - Pubmed
  • Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. - Pubmed
DTHybrid score 0.4624
D(1B) dopamine receptor
Name D(1B) dopamine receptor
Gene Name DRD5
Pharmacological action yes
Actions antagonist
References
  • Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. - Pubmed
  • Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. - Pubmed
DTHybrid score 0.2485
D(2) dopamine receptor
Name D(2) dopamine receptor
Gene Name DRD2
Pharmacological action yes
Actions antagonist
References
  • Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G: Conventional and Atypical Antipsychotics in the Elderly : A Review. Clin Drug Investig. 2003;23(5):287-322. - Pubmed
  • Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. - Pubmed
  • Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 0.5358
Alpha-1A adrenergic receptor
Name Alpha-1A adrenergic receptor
Gene Name ADRA1A
Pharmacological action unknown
Actions antagonist
References
  • Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. - Pubmed
DTHybrid score 0.5076
Alpha-2A adrenergic receptor
Name Alpha-2A adrenergic receptor
Gene Name ADRA2A
Pharmacological action unknown
Actions antagonist
References
  • Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. - Pubmed
DTHybrid score 0.4751
5-hydroxytryptamine 2A receptor
Name 5-hydroxytryptamine 2A receptor
Gene Name HTR2A
Pharmacological action unknown
Actions antagonist
References
  • Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. - Pubmed
  • Gjerden P, Slordal L, Bramness JG: Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol. 2009 Jul 31. - Pubmed
  • Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. - Pubmed
DTHybrid score 0.4171

Enzymes


Cytochrome P450 2D6
Name Cytochrome P450 2D6
Gene Name CYP2D6
Actions substrate
References
  • Flockhart DA. - Drug Interactions: Cytochrome P450 Drug Interaction Table
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.4272

Predictions


Id Partner name Gene Name Score
4512 Cytochrome P450 3A4 CYP3A4 0.2335
320 5-hydroxytryptamine 1A receptor HTR1A 0.2099
632 Alpha-1B adrenergic receptor ADRA1B 0.208
629 Alpha-2B adrenergic receptor ADRA2B 0.2066
590 5-hydroxytryptamine 2C receptor HTR2C 0.1989
378 Alpha-2C adrenergic receptor ADRA2C 0.1983
638 D(3) dopamine receptor DRD3 0.193
432 D(4) dopamine receptor DRD4 0.1877
4200 Cytochrome P450 1A2 CYP1A2 0.1717
492 Histamine H1 receptor HRH1 0.1348
1588 Multidrug resistance protein 1 ABCB1 0.1264
725 5-hydroxytryptamine 1D receptor HTR1D 0.1212
436 5-hydroxytryptamine 2B receptor HTR2B 0.1176
885 5-hydroxytryptamine 1B receptor HTR1B 0.113
103 Muscarinic acetylcholine receptor M1 CHRM1 0.1114
789 Alpha-1D adrenergic receptor ADRA1D 0.1099
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0977
716 5-hydroxytryptamine 7 receptor HTR7 0.0951
4757 Cytochrome P450 2C9 CYP2C9 0.0937
6016 Cytochrome P450 2C19 CYP2C19 0.0931
824 Sodium-dependent serotonin transporter SLC6A4 0.0871
6145 Solute carrier family 22 member 1 SLC22A1 0.0712
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0704
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0704
4118 Cytochrome P450 3A5 CYP3A5 0.0701
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0685
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0678
1256 5-hydroxytryptamine 6 receptor HTR6 0.0614
6013 Cytochrome P450 2E1 CYP2E1 0.0604
6107 Cytochrome P450 3A7 CYP3A7 0.0595
766 Beta-2 adrenergic receptor ADRB2 0.0592
713 Sodium-dependent dopamine transporter SLC6A3 0.058
193 Beta-1 adrenergic receptor ADRB1 0.0577
6030 Cytochrome P450 2B6 CYP2B6 0.0554
131 Synaptic vesicular amine transporter SLC18A2 0.0544
4924 Cytochrome P450 2C8 CYP2C8 0.051
3941 Amine oxidase [flavin-containing] A MAOA 0.0481
587 Serum albumin ALB 0.0479
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0456
341 5-hydroxytryptamine 3 receptor HTR3A 0.0389
3876 Aromatic-L-amino-acid decarboxylase DDC 0.035
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0345
528 5-hydroxytryptamine 1E receptor HTR1E 0.0343
6144 Solute carrier family 22 member 2 SLC22A2 0.0334
465 Calmodulin CALM1 0.0329
6024 Cytochrome P450 1A1 CYP1A1 0.031
3923 Cholinesterase BCHE 0.0309
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0261
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.0244
3939 Amine oxidase [flavin-containing] B MAOB 0.0235
6147 Solute carrier family 22 member 3 SLC22A3 0.0227
118 Organic cation/carnitine transporter 2 SLC22A5 0.0227
94 5-hydroxytryptamine 4 receptor HTR4 0.0219
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0215
174 Sigma 1-type opioid receptor SIGMAR1 0.0214
5718 Cytochrome P450 2A6 CYP2A6 0.0212
750 Voltage-dependent calcium channel gamma-1 subunit CACNG1 0.02
124 Histamine H2 receptor HRH2 0.0186
3426 Glutamine synthetase glnA 0.0183
3987 Glutamine synthetase GLUL 0.0183
474 Acetylcholinesterase ACHE 0.018
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0171
923 Glutamate receptor 3 GRIA3 0.0149
3810 Catechol O-methyltransferase COMT 0.0147
5251 Carbonyl reductase [NADPH] 1 CBR1 0.0146
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0144
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0142
696 Kappa-type opioid receptor OPRK1 0.0139
866 Large neutral amino acids transporter small subunit 2 SLC7A8 0.0136
6106 Cytochrome P450 2C18 CYP2C18 0.0136
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0134
245 Large neutral amino acids transporter small subunit 1 SLC7A5 0.0127
6151 Monocarboxylate transporter 10 SLC16A10 0.0119
847 Mu-type opioid receptor OPRM1 0.0113
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0111
20 Prostaglandin G/H synthase 1 PTGS1 0.011
1517 Beta-3 adrenergic receptor ADRB3 0.0109
467 Delta-type opioid receptor OPRD1 0.0105
828 Phenylalanine-4-hydroxylase PAH 0.0104
3109 Phenylalanine-4-hydroxylase phhA 0.0104
833 Organic cation/carnitine transporter 1 SLC22A4 0.01
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0099
1636 Trace amine-associated receptor 1 TAAR1 0.0097
921 Glutamate receptor 2 GRIA2 0.0092
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0089
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0089
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0086
4120 NADPH--cytochrome P450 reductase POR 0.0081
776 Bile salt export pump ABCB11 0.0081
153 Dopamine beta-hydroxylase DBH 0.0081
1898 Cytochrome P450 1B1 CYP1B1 0.0079
6859 Protein S100-A4 S100A4 0.0076
1656 CYP2B protein CYP2B 0.0076
6070 Nischarin NISCH 0.0075
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.0075
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0074
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.0073
6432 Transporter snf 0.0072
380 Cytochrome P450 17A1 CYP17A1 0.0069
709 ATP-sensitive inward rectifier potassium channel 1 KCNJ1 0.0068
464 Glutamate [NMDA] receptor subunit epsilon-2 GRIN2B 0.0066
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0064
3947 Xanthine dehydrogenase/oxidase XDH 0.0064
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.0063
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.0062
6020 Aldehyde oxidase AOX1 0.0062
862 Multidrug resistance-associated protein 1 ABCC1 0.006
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0057
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0056
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0055
164 Histamine H4 receptor HRH4 0.0055
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0053
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0053
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0053
731 HIV-1 protease HIV-1 protease 0.0052
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0051
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.005
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.005
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0049
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.0049
2112 Toll-like receptor 9 TLR9 0.0044
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0043
6138 Multidrug resistance protein 3 ABCB4 0.0043
1729 Solute carrier family 22 member 6 SLC22A6 0.0041
6100 BDNF/NT-3 growth factors receptor NTRK2 0.004
694 Matrix protein 2 M 0.0039
360 Ribonucleoside-diphosphate reductase large subunit RRM1 0.0039
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0038
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0037
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0037
15 Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I 0.0036
233 Potassium channel subfamily K member 2 KCNK2 0.0035
1618 High affinity nerve growth factor receptor NTRK1 0.0035
4099 Gamma-aminobutyric-acid receptor subunit beta-3 GABRB3 0.0035
535 Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G 0.0034
427 Substance-P receptor TACR1 0.0034
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0034
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.0033
6506 Stathmin-4 STMN4 0.0033
6182 Cytochrome P450 2J2 CYP2J2 0.0033
173 Toll-like receptor 7 TLR7 0.0033
198 Sodium channel protein type 10 subunit alpha SCN10A 0.0033
817 DNA topoisomerase 2-alpha TOP2A 0.0033
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0032
4199 Sphingosine 1-phosphate receptor Edg-8 S1PR5 0.0031
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.003
1360 Sphingomyelin phosphodiesterase SMPD1 0.003
620 Bifunctional dihydrofolate reductase-thymidylate synthase Not Available 0.003
565 Extracellular calcium-sensing receptor CASR 0.0028
6031 Cytochrome P450 3A43 CYP3A43 0.0028
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0028
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0027
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0027
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.0026
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.0026
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0025
3811 Cytochrome P450 19A1 CYP19A1 0.0025
1374 Natriuretic peptides B NPPB 0.0025
1827 Gap junction alpha-1 protein GJA1 0.0025
1908 Vascular cell adhesion protein 1 VCAM1 0.0025
891 Dihydropteroate synthase folP 0.0025
5359 Dihydropteroate synthase folP 0.0025
7175 Dihydropteroate synthase sulI 0.0025
161 Tubulin beta chain TUBB 0.0024
312 Tubulin beta chain TUB2 0.0024
631 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 0.0024
3387 3-hydroxy-3-methylglutaryl-coenzyme A reductase mvaA 0.0024
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0024
385 Potassium-transporting ATPase alpha chain 1 ATP4A 0.0022
504 Mast/stem cell growth factor receptor KIT 0.0022
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.0021
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0021
904 Glutathione S-transferase P GSTP1 0.0021
952 Dipeptidyl peptidase 4 DPP4 0.0021
63 Malate dehydrogenase mdh 0.0021
2329 Malate dehydrogenase mdh 0.0021
3445 Malate dehydrogenase mdh 0.0021
4420 Malate dehydrogenase mdh 0.0021
4438 Malate dehydrogenase mdh 0.0021
365 Dihydrofolate reductase DHFR 0.002
2381 Dihydrofolate reductase DFR1 0.002
2833 Dihydrofolate reductase Not Available 0.002
2931 Dihydrofolate reductase folA 0.002
3544 Dihydrofolate reductase folA 0.002
3682 Dihydrofolate reductase folA 0.002
6642 Dihydrofolate reductase folA 0.002
6756 Dihydrofolate reductase dfrA 0.002
4203 Histamine N-methyltransferase HNMT 0.0019
183 Vascular endothelial growth factor A VEGFA 0.0019
290 Prostaglandin G/H synthase 2 PTGS2 0.0019
2164 Multidrug resistance-associated protein 4 ABCC4 0.0019
871 Glucocorticoid receptor NR3C1 0.0019
200 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 0.0019
451 Carnitine O-palmitoyltransferase I, liver isoform CPT1A 0.0019
893 [Citrate [pro-3S]-lyase] ligase citC 0.0018
845 Pyruvate dehydrogenase [cytochrome] poxB 0.0018
844 Epidermal growth factor receptor EGFR 0.0018
327 Glutathione reductase gor 0.0018
5110 Glutathione reductase GR2 0.0018
1178 Adenosine A2a receptor ADORA2A 0.0018
748 5'-AMP-activated protein kinase catalytic subunit alpha-1 PRKAA1 0.0018
650 Aldo-keto reductase family 1 member C3 AKR1C3 0.0017
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0017
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.0017
146 Androgen receptor AR 0.0016
4209 ATP-sensitive inward rectifier potassium channel 8 KCNJ8 0.0016
4228 Keratin, type II cytoskeletal 7 KRT7 0.0016
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0016
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0016
6220 Aryl hydrocarbon receptor AHR 0.0016
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0016
468 Cytochrome P450 4A11 CYP4A11 0.0016
1629 Transcription factor AP-1 JUN 0.0016
6180 UDP-glucuronosyltransferase 2B4 UGT2B4 0.0016
6142 Solute carrier family 22 member 8 SLC22A8 0.0016
982 Cocaine- and amphetamine-regulated transcript protein CARTPT 0.0015
238 Peroxisome proliferator-activated receptor gamma PPARG 0.0015
4604 Liver carboxylesterase 1 CES1 0.0015
1050 Bile salt sulfotransferase SULT2A1 0.0014
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0014
3086 Plasmepsin-2 Not Available 0.0014
373 Transthyretin TTR 0.0014
485 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE3A 0.0014
4148 Serine/threonine-protein kinase mTOR MTOR 0.0014
738 Monocarboxylate transporter 1 SLC16A1 0.0014
208 DNA-directed RNA polymerase beta' chain rpoC 0.0014
5774 DNA-directed RNA polymerase beta' chain rpoC 0.0014
6143 Solute carrier family 22 member 7 SLC22A7 0.0013
698 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 0.0013
3404 Exotoxin A eta 0.0013
17 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 0.0013
950 Alpha platelet-derived growth factor receptor PDGFRA 0.0013
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0013
860 Nicotinamide N-methyltransferase NNMT 0.0013
699 Nicotinic acid receptor 1 GPR109A 0.0013
928 Nicotinic acid receptor 2 GPR109B 0.0013
583 Nicotinate-nucleotide pyrophosphorylase [carboxylating] QPRT 0.0013
2442 Nicotinate-nucleotide pyrophosphorylase [carboxylating] nadC 0.0013
2459 Nicotinate-nucleotide pyrophosphorylase [carboxylating] nadC 0.0013
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0012
1010 Cytochrome P450 51A1 CYP51A1 0.0012
232 Corticosteroid-binding globulin SERPINA6 0.0012
3856 Fibroblast growth factor receptor 3 FGFR3 0.0012
228 Beta platelet-derived growth factor receptor PDGFRB 0.0012
5766 NAD-dependent deacetylase sirtuin-5 SIRT5 0.0012
6102 Arylamine N-acetyltransferase 2 NAT2 0.0012
6148 Multidrug resistance-associated protein 7 ABCC10 0.0012
473 L-lactate dehydrogenase A chain LDHA 0.0011
6014 Cytochrome P450 2A13 CYP2A13 0.0011
707 72 kDa type IV collagenase MMP2 0.0011
2290 ADP-ribosyl cyclase 2 BST1 0.001
614 Progesterone receptor PGR 0.001
2300 Lysozyme E 0.001
3633 Lysozyme R 0.001
5597 Lysozyme 17 0.001
407 Vascular endothelial growth factor receptor 2 KDR 0.001
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.001
4311 tRNA TRDMT1 0.001
4325 tRNA trmD 0.001
4328 tRNA trmD 0.001
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.001
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.001
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.001
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.001
260 Cytochrome P450 51 ERG11 0.001
761 Cytochrome P450 51 ERG11 0.001
3163 Cytochrome P450 51 cyp51 0.001
144 Hemoglobin subunit alpha HBA1 0.001
518 Peroxidase/catalase T katG 0.001
777 Tumor necrosis factor TNF 0.0009
6154 Multidrug and toxin extrusion protein 1 SLC47A1 0.0009
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0009
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0009
837 Glutamate [NMDA] receptor subunit epsilon-1 GRIN2A 0.0009
3126 Poly [ADP-ribose] polymerase 1 PARP1 0.0009
1064 DNA (cytosine-5)-methyltransferase 1 DNMT1 0.0009
563 Thyroid peroxidase TPO 0.0009
147 Aldehyde dehydrogenase, mitochondrial ALDH2 0.0009
65 Matrix metalloproteinase-9 Not Available 0.0009
26 Vascular endothelial growth factor receptor 3 FLT4 0.0009
295 Carbonic anhydrase 1 CA1 0.0009
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.0009
4122 Histone deacetylase 2 HDAC2 0.0009
16 Adenosine A1 receptor ADORA1 0.0009
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.0009
32 Vascular endothelial growth factor receptor 1 FLT1 0.0009
634 Squalene monooxygenase SQLE 0.0009
7196 Squalene monooxygenase ERG1 0.0009
204 cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 0.0009
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.0009
1262 Corticotropin-lipotropin POMC 0.0008
1341 Histamine H3 receptor HRH3 0.0008
3932 Glutathione S-transferase A2 GSTA2 0.0008
537 ATP synthase delta chain, mitochondrial ATP5D 0.0008
1192 Sulfotransferase 1A1 SULT1A1 0.0008
778 Cysteinyl leukotriene receptor 1 CYSLTR1 0.0008
522 26S proteasome non-ATPase regulatory subunit 2 PSMD2 0.0008
515 26S proteasome non-ATPase regulatory subunit 1 PSMD1 0.0008
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.0008
165 FL cytokine receptor FLT3 0.0008
244 Angiotensin-converting enzyme ACE 0.0008
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0008
6126 Carbonic anhydrase 7 CA7 0.0008
6212 Tubulin gamma-1 chain TUBG1 0.0008
6210 Tubulin delta chain TUBD1 0.0008
6211 Tubulin epsilon chain TUBE1 0.0008
2180 3-phosphoinositide-dependent protein kinase 1 PDPK1 0.0008
4177 Proto-oncogene tyrosine-protein kinase receptor ret RET 0.0008
482 Glycine receptor subunit alpha-1 GLRA1 0.0008
500 Monocarboxylate transporter 4 SLC16A3 0.0008
70 Type-1 angiotensin II receptor AGTR1 0.0008
1974 Oligopeptide transporter, kidney isoform SLC15A2 0.0008
6137 Multidrug resistance-associated protein 6 ABCC6 0.0008
606 Cytochrome P450 27, mitochondrial CYP27A1 0.0007
541 cAMP-specific 3',5'-cyclic phosphodiesterase 4B PDE4B 0.0007
3854 Basic fibroblast growth factor receptor 1 FGFR1 0.0007
122 P2Y purinoceptor 12 P2RY12 0.0007
6136 Multidrug resistance-associated protein 5 ABCC5 0.0007
581 Cytochrome P450 2R1 CYP2R1 0.0007
580 Gamma-aminobutyric-acid receptor subunit alpha-3 GABRA3 0.0007
423 Gamma-aminobutyric-acid receptor subunit alpha-2 GABRA2 0.0007
439 Glutamate [NMDA] receptor subunit epsilon-4 GRIN2D 0.0007
5878 Alpha-7 nicotinic cholinergic receptor subunit CHRFAM7A 0.0007
6038 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6H 0.0007
505 Glutamate [NMDA] receptor subunit epsilon-3 GRIN2C 0.0007
4773 Deoxycytidine kinase DCK 0.0007
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0007
1992 Vitamin D-binding protein GC 0.0007
319 Opioid receptor, sigma 1 OPRS1 0.0007
368 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA 0.0007
3228 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0007
3678 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0007
6856 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0007
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0007
7 Nitric oxide synthase, inducible NOS2 0.0007
6037 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6G 0.0007
737 Mineralocorticoid receptor NR3C2 0.0006
401 Glutamate [NMDA] receptor subunit zeta-1 GRIN1 0.0006
592 Carbonic anhydrase 4 CA4 0.0006
976 Platelet glycoprotein IX GP9 0.0006
4103 Proteasome subunit beta type 2 PSMB2 0.0006
4102 Proteasome subunit beta type 5 PSMB5 0.0006
4101 Proteasome subunit beta type 1 PSMB1 0.0006
1630 Integrin beta-2 ITGB2 0.0006
2450 Tyrosine-protein kinase ITK/TSK ITK 0.0006
3970 Voltage-dependent N-type calcium channel subunit alpha-1B CACNA1B 0.0006
2216 Fibroblast growth factor receptor 4 FGFR4 0.0006
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0006
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0006
806 Sodium/potassium-transporting ATPase alpha-1 chain ATP1A1 0.0006
814 Ryanodine receptor 1 RYR1 0.0006
511 5-hydroxytryptamine 1F receptor HTR1F 0.0006
6141 Sodium/bile acid cotransporter SLC10A1 0.0006
6146 High affinity copper uptake protein 1 SLC31A1 0.0006
4100 Gamma-aminobutyric-acid receptor subunit beta-2 GABRB2 0.0006
1757 Myeloperoxidase MPO 0.0006
2449 Tubulin alpha-3 chain TUBA1A 0.0006
6046 Voltage-gated calcium channel beta 1 subunit splice variant CavB1d CACNB1 0.0006
705 Glutamate receptor 1 GRIA1 0.0006
6048 Troponin C, skeletal muscle TNNC2 0.0005
543 Penicillin-binding protein 1B mrcB 0.0005
6186 Penicillin-binding protein 1B ponB 0.0005
6822 Penicillin-binding protein 1b pbp1b 0.0005
6844 Penicillin-binding protein 1b pbp1b 0.0005
645 Penicillin-binding protein 1A mrcA 0.0005
5805 Penicillin-binding protein 1A ponA 0.0005
6185 Penicillin-binding protein 1A mrcA 0.0005
6799 Penicillin-binding protein 1A pbpA 0.0005
268 Adenosine A2b receptor ADORA2B 0.0005
159 Penicillin-binding protein 2B penA 0.0005
6121 Penicillin-binding protein 2B penA 0.0005
6044 Serum paraoxonase/lactonase 3 PON3 0.0005
1024 Solute carrier family 22 member 11 SLC22A11 0.0005
6045 Voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 0.0005
856 Vitamin D3 receptor VDR 0.0005
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0005
572 Integrin alpha-L ITGAL 0.0005
3868 Calcineurin subunit B isoform 2 PPP3R2 0.0005
357 Carbonic anhydrase 2 CA2 0.0005
421 Calcium signal-modulating cyclophilin ligand CAMLG 0.0005
1864 RET proto-oncogene RET 0.0005
1950 Epithelial discoidin domain-containing receptor 1 DDR1 0.0005
6094 BCR/ABL fusion protein isoform X9 BCR/ABL fusion 0.0005
6170 ATP-binding cassette sub-family A member 3 ABCA3 0.0005
6824 Tyrosine-protein kinase Lyn LYN 0.0005
1275 Estrogen sulfotransferase SULT1E1 0.0004
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.0004
136 Estrogen receptor ESR1 0.0004
760 Fibroblast growth factor 1 FGF1 0.0004
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0004
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0004
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0004
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0004
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0004
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0004
1768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit GNG2 0.0004
1581 G protein-activated inward rectifier potassium channel 2 KCNJ6 0.0004
1571 G protein-activated inward rectifier potassium channel 1 KCNJ3 0.0004
1268 Neuropeptide S receptor NPSR1 0.0004
5787 Angiopoietin-1 receptor TEK 0.0004
230 ATP-binding cassette transporter sub-family C member 8 ABCC8 0.0004
823 Fibroblast growth factor receptor 2 FGFR2 0.0004
291 Nitric-oxide synthase, endothelial NOS3 0.0004
5934 Cytochrome P450 26A1 CYP26A1 0.0004
751 Potassium channel subfamily K member 6 KCNK6 0.0004
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0004
6172 ATP-binding cassette sub-family B member 8, mitochondrial ABCB8 0.0004
6073 Potassium channel subfamily K member 9 KCNK9 0.0004
6072 Potassium channel subfamily K member 3 KCNK3 0.0004
3937 Fatty-acid amide hydrolase FAAH 0.0004
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0004
172 Potassium channel subfamily K member 1 KCNK1 0.0004
40 RAF proto-oncogene serine/threonine-protein kinase RAF1 0.0004
1524 Peptidyl-prolyl cis-trans isomerase A PPIA 0.0004
6700 Peptidyl-prolyl cis-trans isomerase A ppiA 0.0004
1971 cAMP-specific 3',5'-cyclic phosphodiesterase 4A PDE4A 0.0004
951 Macrophage colony-stimulating factor 1 receptor CSF1R 0.0004
84 Nuclear receptor 0B1 NR0B1 0.0004
337 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial NDUFS7 0.0004
214 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3 0.0004
803 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial NDUFS2 0.0004
3957 Adenosine deaminase ADA 0.0004
6168 Solute carrier family 22 member 16 SLC22A16 0.0003
937 Proto-oncogene tyrosine-protein kinase LCK LCK 0.0003
6861 Alcohol dehydrogenase [NADP+] AKR1A1 0.0003
6140 Ileal sodium/bile acid cotransporter SLC10A2 0.0003
469 Annexin A1 ANXA1 0.0003
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.0003
6091 Gamma-aminobutyric acid receptor subunit theta GABRQ 0.0003
2207 Rhodopsin RHO 0.0003
6086 Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 0.0003
6090 Gamma-aminobutyric acid receptor subunit pi GABRP 0.0003
6092 Gamma-aminobutyric acid receptor subunit rho-2 GABRR2 0.0003
6088 Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 0.0003
6115 Gamma-aminobutyric acid receptor subunit rho-3 GABRR3 0.0003
6087 Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 0.0003
6093 Gamma-aminobutyric acid receptor subunit delta GABRD 0.0003
6089 Gamma-aminobutyric acid receptor subunit epsilon GABRE 0.0003
142 Gamma-aminobutyric-acid receptor subunit rho-1 GABRR1 0.0003
4098 Gamma-aminobutyric-acid receptor subunit beta-1 GABRB1 0.0003
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0003
841 Gamma-aminobutyric-acid receptor subunit alpha-6 GABRA6 0.0003
530 Gamma-aminobutyric-acid receptor subunit alpha-4 GABRA4 0.0003
523 Gamma-aminobutyric-acid receptor subunit alpha-5 GABRA5 0.0002
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0002
869 Estrogen receptor beta ESR2 0.0002
76 Nitric-oxide synthase, brain NOS1 0.0002
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0002
↑